We are developing novel siRNA therapies for the treatment of chronic diseases, anchored by three mega blockbuster franchises.
| Program | Target | Delivery Method | Indication | Pre-Clinical / IND |
Phase 1 |
Phase 2 |
Region | Commercial Rights / Partner | Next Milestone |
|---|---|---|---|---|---|---|---|---|---|
SRSD107  |
FXI | Liver | VTE |
|
|
Global Rights under Co-deve-lopment2.3 |
2H2026 Interim Data Readout | ||
| CVD1 |
|
|
Expected to commence in 4Q2025 | ||||||
SRSD216  |
Lp(a) | Liver | CVD / Lipid |
|
|
Global | 1H2026 Interim Follow-up Data (6M) 2H2026 Interim Follow-up Data (1Y) | ||
SRSD384 |
INHBE | Liver | Obesity |
|
Global | Mid-2026 IND |
| Program | Target | Delivery Method | Indication | Pre-Clinical / IND |
Phase 1 |
Phase 2 |
Region | Commercial Rights / Partner | Next Milestone |
|---|---|---|---|---|---|---|---|---|---|
SRNDC-01 |
Undisclosed | Liver | Hypertension |
|
Global | ||||
SRNDC-02 |
Undisclosed | Liver | Hypertension |
|
Global | ||||
SRNDC-03 |
Undisclosed | Liver | Hypertension |
|
Global |
| Program | Target | Delivery Method | Indication | Pre-Clinical / IND |
Phase 1 |
Phase 2 |
Region | Commercial Rights / Partner | Next Milestone |
|---|---|---|---|---|---|---|---|---|---|
SRNDM-01 |
Undisclosed | Liver | Hypertension |
|
Global | ||||
SRNDM-02 |
Undisclosed | Adipose | Cardiometabolic |
|
Global | ||||
SRNDM-03 |
Undisclosed | Liver | Cardiometabolic |
|
Global | ||||
SRNDM-04 |
Undisclosed | Liver | Cardiometabolic |
|
Global | ||||
SRNDM-05 |
Undisclosed | Adipose | Cardiometabolic |
|
Global | ||||
SRNDM-06 |
Undisclosed | Heart | Heart Failure |
|
Global | ||||
SRNDM-07 |
Undisclosed | Heart | Heart Failure |
|
Global |
| Program | Target | Delivery Method | Indication | Pre-Clinical / IND |
Phase 1 |
Phase 2 |
Region | Commercial Rights / Partner | Next Milestone |
|---|---|---|---|---|---|---|---|---|---|
SRNDO-01 |
Undisclosed | Adipose | Obesity |
|
Global | ||||
SRNDO-02 |
Undisclosed | Adipose | Obesity |
|
Global | ||||
SRNDO-03 |
Undisclosed | Adipose | Obesity |
|
Global | ||||
SRNDO-04 |
Undisclosed | Adipose | Obesity |
|
Global | ||||
SRNDO-05 |
Undisclosed | Skeletal Muscle | Muscle Wasting |
|
Global |
| Program | Target | Delivery Method | Indication | Pre-Clinical / IND |
Phase 1 |
Phase 2 |
Region | Commercial Rights / Partner | Next Milestone |
|---|---|---|---|---|---|---|---|---|---|
SRNDE-01 |
Undisclosed | Liver | Complement Disorders |
|
Global | ||||
SRNDE-02 |
Undisclosed | Kidney | CKD |
|
Global | ||||
Five Targets |
Undisclosed | CNS | CNS |
|
Global |
Core Product Key Product
Source:
A1 prospectus
Notes:
1 The Phase II VTE and CVD study both leverage data from the same indication-agnostic Phase 1 trials; No separate Phase 1 trial is ongoing.
2 Jointly developed through a co-collaboration with CRISPR Therapeutics.
3 We grant CRISPR options to exclusively license up to two licensed targets for research, development, manufacture and commercialization.
Abbreviations:
VTE = venous thromboebolism, CVD = cardiovascular disease, CKD = chronic kidney disease.
Sirius Therapeutics, Inc., all rights reserved
为了更好的呈现效果，移动端请竖屏浏览
